ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023
Preanalytical stability of plasma/serum brain-derived tau.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Evaluation of Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid, Serum, and Plasma Using the Fully Automated Lumipulse Platform.Journal of clinical laboratory analysis · 2026Article
- Evaluation of serum as an alternative matrix to plasma for NULISA‑based proteomic blood biomarker measurements.Scientific reports · 2026Article
- Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay.Scientific reports · 2026Article
- Prognostic value of plasma biomarkers in early Alzheimer's disease: a longitudinal clinical and neuroimaging study.Alzheimer's research & therapy · 2025Observational
- Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform.medRxiv : the preprint server for health sciences · 2025Article
- Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay.medRxiv : the preprint server for health sciences · 2025Article
- Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.Alzheimer's research & therapy · 2025Article
- Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study.European journal of neurology · 2025Article
- Impact of prior exposures on biomarkers of blast during military tactical training.Frontiers in neurology · 2025Article
- Blood-based biomarkers and neuroimaging for early detection of post-stroke cognitive impairment: current evidence and synergistic prospects.Frontiers in neurology · 2025Review
- Effect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer's disease plasma biomarkers.Journal of neurochemistry · 2024Article
- Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.Molecular neurodegeneration · 2024Review
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease.Nature communications · 2024Article
- The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients.Alzheimer's & dementia (New York, N. Y.)Article
- Brain-derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Funding
Abstract
introductionWe investigated the effects of matrix type and reagent batch changes on diagnostic performances and longitudinal trajectories of brain-derived tau (BD-tau).
methodsWe evaluated (i) Cohort 1: paired EDTA plasma and serum from Alzheimer biomarker-positive older adults versus controls (n = 26); and (ii) Cohort 2: n = 79 acute ischemic stroke patients with 265 longitudinal samples across four time points.
resultsIn Cohort 1, plasma and serum BD-tau were strongly correlated (rho = 0.96, p < 0.0001) with similar diagnostic performances (AUCs >99%) and correlations with CSF total-tau (rho = 0.93-0.94, p < 0.0001). However, absolute concentrations were ∼40% higher in plasma versus serum. In Cohort 2, first and repeated BD-tau measurements showed a near-perfect correlation (rho = 0.96, p < 0.0001), with no significant between-batch concentration differences. In longitudinal analyses, substituting ∼10% of the first-run concentrations for the remeasured values showed overlapping estimated trajectories without significant differences at any time point. DISCUSSION: BD-tau has equivalent diagnostic accuracies, but non-interchangeable absolute concentrations, in plasma versus serum. Furthermore, the analytical robustness is unaffected by batch-to-batch reagent variations. HIGHLIGHTS: Brain-derived tau (BD-tau) is a novel blood-based biomarker that quantifies tau protein of CNS origin. Effects of preanalytical handling procedures on the quality and reproducibility of BD-tau measures are unknown. In two cohorts of n = 105 participants, we compared BD-tau concentrations and diagnostic performances in paired plasma and serum samples, and evaluated impacts of batch-to-batch reagent variations. Paired plasma and serum showed equivalent diagnostic performances to separate amyloid-positive AD from amyloid-negative controls, indicating both can be used independently. Repeated measurements and longitudinal trajectories of plasma BD-tau were unaffected by batch-to-batch reagent variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.